1,3,5-TrihydroxyxanthoneCAS# 6732-85-0 |
2D Structure
Quality Control & MSDS
3D structure
Package In Stock
Number of papers citing our products
Cas No. | 6732-85-0 | SDF | Download SDF |
PubChem ID | 5281663 | Appearance | Yellow powder |
Formula | C13H8O5 | M.Wt | 244.2 |
Type of Compound | Xanthones | Storage | Desiccate at -20°C |
Solubility | Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc. | ||
Chemical Name | 1,3,5-trihydroxyxanthen-9-one | ||
SMILES | C1=CC2=C(C(=C1)O)OC3=CC(=CC(=C3C2=O)O)O | ||
Standard InChIKey | XESIWQIMUSNPRO-UHFFFAOYSA-N | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Description | 1. 1,3,5-Trihydroxyxanthone has selective inhibitory activity on platelet aggregation induced by adenosine diphosphate. |
1,3,5-Trihydroxyxanthone Dilution Calculator
1,3,5-Trihydroxyxanthone Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 4.095 mL | 20.475 mL | 40.95 mL | 81.9001 mL | 102.3751 mL |
5 mM | 0.819 mL | 4.095 mL | 8.19 mL | 16.38 mL | 20.475 mL |
10 mM | 0.4095 mL | 2.0475 mL | 4.095 mL | 8.19 mL | 10.2375 mL |
50 mM | 0.0819 mL | 0.4095 mL | 0.819 mL | 1.638 mL | 2.0475 mL |
100 mM | 0.041 mL | 0.2048 mL | 0.4095 mL | 0.819 mL | 1.0238 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- Kaurenoic acid
Catalog No.:BCN4600
CAS No.:6730-83-2
- 2-Hydroxy-4-methoxybenzaldehyde
Catalog No.:BCN7798
CAS No.:673-22-3
- H-Asp(OtBu)-OMe.HCl
Catalog No.:BCC2892
CAS No.:2673-19-0
- H-D-Phe-OH
Catalog No.:BCC3012
CAS No.:673-06-3
- Kansuinine E
Catalog No.:BCN3769
CAS No.:672945-84-5
- 3-O-(2'E ,4'Z-decadienoyl)-20-deoxyingenol
Catalog No.:BCN1382
CAS No.:672941-64-9
- Kif15-IN-2
Catalog No.:BCC5153
CAS No.:672926-33-9
- Kif15-IN-1
Catalog No.:BCC5152
CAS No.:672926-32-8
-
γDGG
Catalog No.:BCC6557
CAS No.:6729-55-1
- SKF 83959 hydrobromide
Catalog No.:BCC7251
CAS No.:67287-95-0
- SKF 81297 hydrobromide
Catalog No.:BCC7071
CAS No.:67287-39-2
- Cabraleadiol
Catalog No.:BCN4224
CAS No.:67253-01-4
- Hexa-D-arginine
Catalog No.:BCC6269
CAS No.:673202-67-0
- (R,R)-Formoterol
Catalog No.:BCC1293
CAS No.:67346-49-0
- Pterokaurane R
Catalog No.:BCN4076
CAS No.:67349-43-3
- Catalposide
Catalog No.:BCN4225
CAS No.:6736-85-2
- Drospirenone
Catalog No.:BCC4493
CAS No.:67392-87-4
- H-D-Lys-OMe.2HCl
Catalog No.:BCC2680
CAS No.:67396-08-1
- 3-O-Acetyl-11-keto-beta-boswellic acid
Catalog No.:BCN1381
CAS No.:67416-61-9
- Z-D-His-OH
Catalog No.:BCC2767
CAS No.:67424-93-5
- (±)-Blebbistatin
Catalog No.:BCC7169
CAS No.:674289-55-5
- Isorhamnetin-3-O-galactoside
Catalog No.:BCC8190
CAS No.:6743-92-6
- Fmoc-Cys(tBu)-OH
Catalog No.:BCC3478
CAS No.:67436-13-9
- Isoasatone A
Catalog No.:BCN7762
CAS No.:67451-73-4
Benzophenones and xanthones from Garcinia cantleyana var. cantleyana and their inhibitory activities on human low-density lipoprotein oxidation and platelet aggregation.[Pubmed:22640928]
Phytochemistry. 2012 Aug;80:58-63.
Three benzophenones, 2,6,3',5'-tetrahydroxybenzophenone (1), 3,4,5,3',5'-pentahydroxybenzophenone (3) and 3,5,3',5'-tetrahydroxy-4-methoxybenzophenone (4), as well as a xanthone, 1,3,6-trihydroxy-5-methoxy-7-(3'-methyl-2'-oxo-but-3'-enyl)xanthone (9), were isolated from the twigs of Garcinia cantleyana var. cantleyana. Eight known compounds, 3,4,5,3'-tetrahydroxy benzophenone (2), 1,3,5-Trihydroxyxanthone (5), 1,3,8-trihydroxyxanthone (6), 2,4,7-trihydroxyxanthone (7), 1,3,5,7-tetrahydroxyxanthone (8), quercetin, glutin-5-en-3beta-ol and friedelin were also isolated. The structures of the compounds were elucidated by spectroscopic methods. The compounds were investigated for their ability to inhibit low-density lipoprotein (LDL) oxidation and platelet aggregation in human whole blood in vitro. Most of the compounds showed strong antioxidant activity with compound 8 showing the highest inhibition with an IC(5)(0) value of 0.5 muM, comparable to that of probucol. Among the compounds tested, only compound 4 exhibited strong inhibitory activity against platelet aggregation induced by arachidonic acid (AA), adenosine diphosphate (ADP) and collagen. Compounds 3, 5 and 8 showed selective inhibitory activity on platelet aggregation induced by ADP.